Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-03-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year ended December 31, 2022, issued by the company's board and management. It discusses the evaluation of the company's internal control effectiveness over financial reporting and non-financial reporting, referencing regulatory internal control standards and defect classification criteria. The content is focused on internal control assessment rather than full financial statements or annual performance. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial data and analysis. It is not an Audit Report (AR) in the traditional sense of an auditor's opinion on financial statements, but rather an internal control evaluation report prepared by the company. The document is substantive and detailed, not a brief announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Given the focus on internal control evaluation and the detailed nature of the report, the best fitting category is Audit Report / Information (AR). FY 2022
2023-03-23 Chinese
金陵药业股份有限公司2022年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report" of Jinling Pharmaceutical Co., Ltd. It details the supervisory board's activities, including oversight of company operations, financial checks, internal controls, and compliance with laws and regulations for the year 2022. It references the audit report issued by the accounting firm but does not itself contain the audit report or full financial statements. The document is a report from the supervisory board summarizing their work and opinions on the company's governance and financial oversight for the year. This type of document is typically classified as an Audit Report / Information (AR) because it focuses on supervisory and audit-related activities rather than being a full annual report or other category. The document length is 3102 characters, which is consistent with a detailed report but not a full annual report. Therefore, the best classification is AR with high confidence. FY 2022
2023-03-23 Chinese
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters discussed at a specific board meeting, including related party transactions, profit distribution proposals, internal control self-evaluation, accounting policy changes, securities investment, remuneration, and appointment of auditors. It references compliance with laws and regulations and expresses agreement with proposals to be submitted to the shareholders' meeting. The document is not a full financial report but rather an independent opinion on board meeting agenda items and related governance matters. It is not an announcement of voting results, nor a proxy solicitation, nor a full annual or interim report. The content aligns with Board/Management Information (MANG) as it relates to board meeting decisions and independent directors' opinions on governance and management issues. The document length is short (2516 characters), and it is not a report publication announcement or certification letter. Therefore, the best classification is MANG with high confidence.
2023-03-23 Chinese
金陵药业股份有限公司关于拟续聘2023年度会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Tianheng CPA Firm) for the 2023 fiscal year to audit the company's financial statements and internal controls. It details the firm's background, personnel, audit fees, and the approval process by the board and audit committee. The document explicitly states that the reappointment is subject to approval at the 2022 annual shareholders meeting. There are no actual financial statements or audit reports included, only information about the appointment process and firm credentials. The document length is under 5,000 characters and it serves as a formal announcement rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information excluding full annual reports. The confidence in this classification is high given the clear focus on audit firm appointment and related audit information. FY 2023
2023-03-23 Chinese
证券投资专项说明
Regulatory Filings Classification · 95% confidence The document is a special explanation by the board of directors of Jinling Pharmaceutical Co., Ltd. regarding the company's securities investment situation for the year 2022. It includes detailed information on securities investment holdings, investment income, fair value changes, and internal control measures related to securities investment. The document references quarterly and half-year reports where these matters were previously disclosed but itself is a focused explanation on securities investment rather than a full financial report. The document length is short (1220 characters), and it is not a full annual or interim report but a specific disclosure related to securities investment. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-23 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the year 2022, including main accounting data, financial indicators, quarterly data, shareholder information, and business overview. The content is comprehensive and covers the company's operating results, financial status, and future plans, which aligns with the characteristics of an Annual Report. The document length is 9424 characters, which is substantial and contains actual financial data, not just an announcement or summary notice. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-03-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.